L-type and N-type voltage-gated calcium channel (None)

L-type and N-type voltage-gated calcium channels are two distinct but related subtypes of high-voltage-activated ion channels that mediate calcium influx in response to membrane depolarization. L-type channels (mainly CaV1.2 and CaV1.3) are predominant in muscle tissue and some neurons, where they control excitation–contraction coupling and hormone secretion. N-type channels (CaV2.2), abundant in neurons, are key mediators of neurotransmitter release, especially in nociceptive pathways and synaptic terminals. Both are multi-subunit complexes with an α1 subunit forming the ion-conducting pore and auxiliary subunits modulating channel function. These channels are implicated in diseases ranging from cardiovascular disorders (L-type) to chronic pain and neurological disorders (N-type), and are targeted by medications including dihydropyridines, phenylalkylamines, benzothiazepines (L-type blockers), and peptide toxins like ziconotide (N-type inhibitor)[1][2][4][5][6][7][8][9][10]. \n\nNote: \nThe name "L-type and N-type voltage-gated calcium channels" collectively designates two closely related but distinct molecular targets. For structured data, it is generally preferable to treat them as separate entities.

Other names

L-type calcium channel (L-type VGCC, CaV1.2, CaV1.3, etc.)N-type calcium channel (N-type VGCC, CaV2.2)Voltage-gated calcium channel (VGCC)—class-level termHigh-voltage-activated calcium channel (for both L-type and N-type)Dihydropyridine receptor (historically for L-type, not N-type)CaV channels (umbrella family, with CaV1.x for L-type, CaV2.2 for N-type)

Blockade of calcium entry through voltage-gated channels, inhibiting excitation-contraction coupling (L-type, muscle), neurotransmitter release (N-type, neurons), and other calcium-dependent cellular processes[2][5][6][8]\nRegulation of heart rate and contractility (L-type blocker)\nInhibition of nociceptive transmission (N-type blocker for pain)